Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$299.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lindsay Androski
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Beta
- 0.62
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- -0.29
Financials
Revenue
$299.0KNet Income
$59.12MEBITDA
$59.14MFree Cash Flow
$239.81MEPS (diluted)
$0.30Shares Outstanding (diluted)
199.63M+267.6%Operating Expenses
$10.57MCash & Debt
$337.49MReturn of Capital
$0.00Revenue by Segment (annual)
$12.72MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.08M | $-33.50M | $-0.17 |
| 2024 | $6.17M | $-69.92M | $-0.38 |
| 2023 | $18.14M | $-72.85M | $-0.44 |
| 2022 | $39.02M | $-69.46M | $-0.46 |
| 2021 | $10.99M | $-76.25M | $-0.73 |
| 2020 | $6.91M | $-63.74M | $-0.86 |
| 2019 | $6.01M | $-153.72M | $-2.69 |
| 2018 | $5.90M | $-57.10M | $-1.03 |
| 2017 | $10.70M | $-84.40M | $-1.54 |
| 2016 | $1.50M | $-384.10M | $-7.24 |
| 2015 | $24.87M | $-61.12M | $-1.34 |
| 2014 | $15.00M | $-38.80M | $-1.80 |
| 2013 | $15.46M | $-14.06M | $-0.92 |
| 2012 | $14.18M | $29.95M | $2.16 |
Valuation
ABUShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·12d ago·Positive
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Genevant
View source ↗ - Newsglobenewswire.com·31d ago·Negative
…nical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (“FDA”) that the clinical hold on the Investigational New Drug (“IND”) application for AB-101 has been removed and that the Company may e…
View source ↗ - Newsglobenewswire.com·52d ago·Negative
…s Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, whic…
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…minary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction…
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
… Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than…
View source ↗ - Newsglobenewswire.com·93d ago·Neutral
… Million of its Common Shares Through Modified “Dutch Auction” Tender Offer WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75…
View source ↗ - Newsglobenewswire.com·102d ago·Positive
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.02 per share
Typical surprise +71.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$0.30 vs $-0.02beat
- Wed, Aug 12$-0.03 vs $-0.02miss
- Wed, May 13$0.87 vs $-0.03beat
- Mon, Mar 23$-0.01 vs $-0.04beat
- Thu, Nov 13$-0.04 vs $-0.06beat
- Wed, Aug 6$0.01 vs $-0.02beat
Estimates and results for ABUS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABUS officers and directors.
- Bought
- —
- Sold
- $363k
0 trades
9 trades
- Hastings David Csold
- Sims Karensold
- Mcelhaugh Michael J.sold
- Naftzger J. Christophersold
- Manchester Keith Ssold
- Sims Karensold
- Hastings David Csold
- Sofia Michael J.sold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABUS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
